Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

Old API Wind-down Ltd - Ordinary Shares > 50 Yosprala scripts per/wk... according to the CC..
View:
Post by kuatolives on Nov 07, 2016 11:11am

50 Yosprala scripts per/wk... according to the CC..

In line with other comparable drug launches.... apparantly.
Comment by Floridas2000 on Nov 07, 2016 12:51pm
Is that good or bad according to Dr. Adams?  I have no context on what that means.
Comment by kuatolives on Nov 07, 2016 1:05pm
They compared the uptake with some other cardio drugs that hit the market in the last few years which came in around 58/per week.  He said he was happy, but what else is he going to say.
Comment by mjh9413 on Nov 07, 2016 2:12pm
I guess one takeaway might be this is with existing salesforce but, gee, that is less than $100K a qtr gross revenues. That won't pay the bills AT ALL. Any one have an idea why outlook shows tempering in expenses when there is meant to be a prevailing build in the salesforce. Also, anyone know if these salespeople are commission/expenses only?
Comment by kuatolives on Nov 07, 2016 2:35pm
Scripts are typically accumulative, so that adds up fast.
Comment by mjh9413 on Nov 07, 2016 4:13pm
kuatolives, what do you mean? I did accumulate the weekl number number. They've gotta grow not simply add up.eom
Comment by kuatolives on Nov 07, 2016 4:54pm
Just saying, at $150/bottle for 30 pills, that's $1800 a year per patient. For the 200 scripts they've written in the first month, assuming the patients keep using them, that's $360,000 added to next year's bottom line. Enter what you think the month to month growth rate will be and you'll have your 2017 Yosprala revenue estimate. Every thousand scripts is $1.8 million to the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities